Skip to main content

Phibro Animal Health Corporatio (PAHC) Stock Analysis

HoldVALUE-TRAP 3/5Moderate Confidence

Healthcare · Drug Manufacturers - Specialty & Generic

Hold if already holding. Not a fresh buy at $34.00, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: United States (57.0%); Concentration risk — Product: Animal Health (74.0%).

Phibro Animal Health is a global animal health and mineral nutrition company marketing approximately 800 product lines in approximately 90 countries to approximately 4,500 customers. Three segments: Animal Health (74% of FY2025 net sales, $963M), Mineral Nutrition (20%), and... Read more

$34.00+17.0% A.UpsideScore 5.4/10#14 of 29 Drug Manufacturers - Specialty & Generic
QualityF-score7 / 9FCF yield-1.29%
IncomeYield1.42%(5y avg 2.56%)Payout20.60%sustainable
Stop $32.06Target $39.67(analyst − 13%)A.R:R 1.1:1
Analyst target$45.60+34.1%5 analysts
$39.67our TP
$34.00price
$45.60mean
$58

Hold if already holding. Not a fresh buy at $34.00, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: United States (57.0%); Concentration risk — Product: Animal Health (74.0%). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Multiple concerning factors. Consider reducing position. | News modifier +1 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Score 5.4/10, moderate confidence.

Passes 5/7 gates (clean insider activity, no SEC red flags, earnings proximity 98d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: aggressive.

Val8.4Qual5.5Grw5.1Mom1.5Sent5.7Ins3.1Peer5.3Tech6.3Risk5.75.4OVERALL

Recent Developments — Phibro Animal Health Corporatio

Latest news

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards
Sector modifier (Healthcare): +0.5
Strong earnings beat streak (4/4)
Earnings estimates trending UP
Risks
Concentration risk — Geographic: United States (57.0%)
Concentration risk — Product: Animal Health (74.0%)
Leverage penalty (D/E 2.2): -1.5

Key Metrics

P/E (TTM)14.5
P/E (Fwd)10.1
Mkt Cap$1.4B
EV/EBITDA8.9
Profit Mgn6.3%
ROE30.3%
Rev Growth10.3%
Beta0.61
Dividend1.42%
Rating analysts10

Quality Signals

Piotroski F7/9MoatNarrow

Options Flow

P/C0.07bullish
IV60%elevated
Max Pain$80+135.3% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHGeographicUnited States57%
    10-K Item 1: 'United States ... _57_| _% _| _57_| _% _| _59_| _%_'
  • HIGHProductAnimal Health74%
    10-K Item 1: 'Animal Health ... _74_| _% _| _69_| _% _| _67_| _%_'

Material Events(8-K, last 90d)

  • 2026-04-14Item 5.02LOW
    Joyce J. Lee resigned from Board of Directors effective April 15, 2026. Resignation was not the result of any disagreement with the Company on any matter relating to operations, policies or practices.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd
0.0
Obv
1.0
Volume
1.3
Ma Position
2.2
Rsi
3.0
Capitulation risk (RSI 22, below 200MA)Volume distribution (falling OBV)Below 200-MA but MA still rising (+8.3%/30d) — pullback in uptrend, not confirmed weakness
GatesMomentum 1.5<4.5A.R:R 1.1 < 1.5@spotInsider activity: OKNo SEC red flagsEARNINGS PROXIMITY 98d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive
RSI
22 · Oversold
↓ 20D MA↓ 50D MA↓ 200D MAGOLDEN CROSSSupport $33.05Resistance $58.74

Price Targets

$32
$40
A.Upside+16.7%
A.R:R1.1:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeRisk-Off

Risk Alerts

! NEWS_MOD=+1: SELL_IF_HOLDING → HOLD_IF_HOLDING
! Momentum score 1.5/10 — below 4.5 minimum
! Reward/Risk 1.1:1 at current price — below 1.5:1 minimum

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-08-26 (98d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is PAHC stock a buy right now?

Hold if already holding. Not a fresh buy at $34.00, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: United States (57.0%); Concentration risk — Product: Animal Health (74.0%). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Multiple concerning factors. Consider reducing position. | News modifier +1 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Target $39.67 (+16.7%), stop $32.06 (−6.1%), A.R:R 1.1:1. Score 5.4/10, moderate confidence.

What is the PAHC stock price target?

Take-profit target: $39.67 (+17.0% upside). Target $39.67 (+16.7%), stop $32.06 (−6.1%), A.R:R 1.1:1. Stop-loss: $32.06.

What are the risks of investing in PAHC?

Concentration risk — Geographic: United States (57.0%); Concentration risk — Product: Animal Health (74.0%); Leverage penalty (D/E 2.2): -1.5.

Is PAHC overvalued or undervalued?

Phibro Animal Health Corporatio trades at a P/E of 14.5 (forward 10.1). TrendMatrix value score: 8.4/10. Verdict: Hold.

What do analysts say about PAHC?

10 analysts cover PAHC with a consensus score of 2.5/5. Average price target: $46.

What does Phibro Animal Health Corporatio do?Phibro Animal Health is a global animal health and mineral nutrition company marketing approximately 800 product lines...

Phibro Animal Health is a global animal health and mineral nutrition company marketing approximately 800 product lines in approximately 90 countries to approximately 4,500 customers. Three segments: Animal Health (74% of FY2025 net sales, $963M), Mineral Nutrition (20%), and Performance Products (6%); total revenue $1.296B. The US represented 57% of FY2025 net sales.

Related stocks: INDV (Indivior Pharmaceuticals, Inc.) · ANIP (ANI Pharmaceuticals, Inc.) · COLL (Collegium Pharmaceutical, Inc.) · BHC (Bausch Health Companies Inc.) · LNTH (Lantheus Holdings, Inc.)